Cell line name | HCC827 GR5 |
---|---|
Synonyms | HCC827-GR5; HCC-827-GR5; HCC827GR5 |
Accession | CVCL_V622 |
Resource Identification Initiative | To cite this cell line use: HCC827 GR5 (RRID:CVCL_V622) |
Comments | Part of: Cancer Cell Line Encyclopedia (CCLE) project. Doubling time: 48 hours (PubMed=25984343). Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa). Omics: Deep exome analysis. Omics: shRNA library screening. |
Sequence variations | Heterozygous for EGFR p.Glu746_Ala750del (c.2236_2250del15) (from parent cell line).Homozygous for TP53 p.Val218del (c.646_648GTG[2]) (c.652_654delGTG) (ClinVar=VCV000634761) (from parent cell line). |
Disease | Lung adenocarcinoma (NCIt: C3512) |
Species of origin | Homo sapiens (Human)
(NCBI Taxonomy: 9606)
|
Hierarchy | Parent: CVCL_2063 (HCC827) |
Sex of cell | Female |
Age at sampling | 39Y |
Category | Cancer cell line |
Publications | PubMed=17463250; DOI=10.1126/science.1141478 PubMed=25984343; DOI=10.1038/sdata.2014.35 PubMed=31068700; DOI=10.1038/s41586-019-1186-3 |
Cross-references | |
Cell line databases/resources | CCLE; HCC827GR5_LUNG
Cell_Model_Passport; SIDM01636 DepMap; ACH-000029 |
Biological sample resources | BioSample; SAMN10988418 |
Chemistry resources | PharmacoDB; HCC827GR5_462_2019 |
Gene expression databases | GEO; GSM466322 |
Other | Wikidata; Q54881790 |
Polymorphism and mutation databases | Progenetix; CVCL_V622 |
Entry history | |
Entry creation | 16-Apr-2014 |
Last entry update | 29-Oct-2020 |
Version number | 12 |